Study finds encouraging results in psilocybin treatment for TRD patients
Mental Health Weekly January 10, 2025 DOI: 10.1002/mhw.34292 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label study Peer reviewed |
|---|---|
| Population | Patients with severe treatment resistant depression |
| Intervention | Synthetic psilocybin |
| Topics | Psilocybin |
| Keywords | Hallucinogen |
| Key points | Synthetic psilocybin significantly reduced depressive symptoms and demonstrated safety and efficacy in patients with severe treatment-resistant depression. |
Abstract
Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open‐label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.